Holen Sie sich die Stockscreener-App
30.72
2.64%
0.79
Handel nachbörslich:
30.73
0.01
+0.03%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt BAX?
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$29.93
Offen:
$29.99
24-Stunden-Volumen:
3.70M
Relative Volume:
0.77
Marktkapitalisierung:
$15.99B
Einnahmen:
$17.28B
Nettoeinkommen (Verlust:
$108.00M
KGV:
153.60
EPS:
0.2
Netto-Cashflow:
$391.00M
1W Leistung:
-1.44%
1M Leistung:
+7.26%
6M Leistung:
-14.76%
1J Leistung:
-14.95%
1-Tages-Spanne:
$29.86
$30.90
1-Wochen-Bereich:
$29.86
$32.60
52-Wochen-Spanne:
$26.25
$40.49
Baxter International Inc Stock (BAX) Company Profile
Firmenname
Baxter International Inc
Sektor
Telefon
(847) 948-2000
Adresse
ONE BAXTER PKWY, DEERFIELD, IL
Vergleichen Sie BAX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
BAX
Baxter International Inc
|
30.72 | 15.99B | 17.28B | 108.00M | 391.00M | 0.20 |
|
ISRG
Intuitive Surgical Inc
|
536.15 | 184.87B | 8.71B | 2.48B | 1.75B | 6.82 |
|
ALC
Alcon Inc
|
96.10 | 48.28B | 9.91B | 1.02B | 665.00M | 2.05 |
|
BDX
Becton Dickinson Co
|
167.14 | 47.99B | 20.87B | 1.50B | 2.59B | 5.24 |
|
RMD
Resmed Inc
|
244.70 | 35.94B | 5.02B | 1.31B | 1.56B | 8.91 |
|
COO
The Cooper Companies, Inc.
|
81.25 | 16.18B | 3.90B | 392.30M | 288.10M | 1.95 |
Baxter International Inc Stock (BAX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-02-26 | Fortgesetzt | Goldman | Buy |
| 2025-02-24 | Hochstufung | Argus | Hold → Buy |
| 2025-02-20 | Fortgesetzt | Barclays | Overweight |
| 2024-07-15 | Herabstufung | Morgan Stanley | Equal-Weight → Underweight |
| 2024-05-30 | Eingeleitet | Goldman | Neutral |
| 2024-05-10 | Herabstufung | TD Cowen | Buy → Hold |
| 2023-05-30 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2023-03-29 | Eingeleitet | UBS | Neutral |
| 2023-01-06 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2023-01-05 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2023-01-03 | Herabstufung | BofA Securities | Buy → Neutral |
| 2022-12-19 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2022-12-15 | Herabstufung | Deutsche Bank | Buy → Hold |
| 2022-12-12 | Herabstufung | Citigroup | Buy → Neutral |
| 2022-10-18 | Eingeleitet | Barclays | Overweight |
| 2022-10-12 | Eingeleitet | Jefferies | Hold |
| 2022-06-24 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2022-04-04 | Herabstufung | Goldman | Neutral → Sell |
| 2022-03-02 | Fortgesetzt | BofA Securities | Buy |
| 2022-02-18 | Bestätigt | KeyBanc Capital Markets | Overweight |
| 2022-02-18 | Bestätigt | Morgan Stanley | Overweight |
| 2022-02-18 | Bestätigt | Raymond James | Outperform |
| 2022-02-18 | Bestätigt | Stifel | Buy |
| 2022-02-18 | Bestätigt | UBS | Neutral |
| 2022-02-18 | Bestätigt | Wells Fargo | Overweight |
| 2022-02-11 | Eingeleitet | Goldman | Neutral |
| 2022-01-07 | Fortgesetzt | Citigroup | Buy |
| 2022-01-07 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2021-09-13 | Hochstufung | Cowen | Market Perform → Outperform |
| 2021-09-03 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2021-05-25 | Eingeleitet | Barclays | Equal Weight |
| 2021-01-29 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2021-01-06 | Herabstufung | UBS | Buy → Neutral |
| 2020-12-15 | Herabstufung | Goldman | Buy → Neutral |
| 2020-10-01 | Hochstufung | Citigroup | Neutral → Buy |
| 2020-09-04 | Herabstufung | Argus | Buy → Hold |
| 2020-06-24 | Eingeleitet | Oppenheimer | Outperform |
| 2020-03-19 | Hochstufung | Stifel | Hold → Buy |
| 2020-03-18 | Hochstufung | KeyBanc Capital Markets | Sector Weight → Overweight |
| 2020-03-05 | Eingeleitet | Citigroup | Neutral |
| 2020-02-13 | Eingeleitet | Goldman | Buy |
| 2020-01-02 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2019-12-17 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2019-06-26 | Eingeleitet | KeyBanc Capital Markets | Sector Weight |
| 2019-04-08 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2019-01-02 | Hochstufung | Citigroup | Neutral → Buy |
| 2019-01-02 | Hochstufung | Morgan Stanley | Underweight → Overweight |
| 2018-11-02 | Hochstufung | Argus | Hold → Buy |
| 2018-10-16 | Eingeleitet | Barclays | Underweight |
| 2018-05-17 | Fortgesetzt | Piper Jaffray | Overweight |
| 2018-02-06 | Bestätigt | Citigroup | Neutral |
| 2018-01-03 | Eingeleitet | Evercore ISI | Outperform |
| 2018-01-03 | Hochstufung | Raymond James | Mkt Perform → Outperform |
Alle ansehen
Baxter International Inc Aktie (BAX) Neueste Nachrichten
Morgan Stanley Cuts Baxter International (NYSE:BAX) Price Target to $28.00 - MarketBeat
Baxter International First Quarter 2025 Earnings: Beats Expectations - Yahoo Finance
Beyond the Balance Sheet: What SWOT Reveals About Baxter Interna - GuruFocus
Baxter International IncDeclares Quarterly Dividend Of $0.17 Per Share - marketscreener.com
Baxter Declares Quarterly Dividend | BAX Stock News - GuruFocus
Baxter Declares Quarterly Dividend - Bluefield Daily Telegraph
Hurricane Helene impact on Baxter to further limit IV fluid supply, HHS says - AOL.com
What Are Wall Street Analysts' Target Price For Baxter International Stock? - Barchart.com
Baxter stock rises on earnings beat, guidance raise - MSN
Baxter International Inc. (NYSE:BAX) Q1 2025 Earnings Call Transcript - Insider Monkey
Health care company says Trump tariffs will cost it $60M–$70M this year - Ars Technica
Baxter International Inc. (NYSE:BAX) Shares Sold by Banco Bilbao Vizcaya Argentaria S.A. - MarketBeat
Baxter Intl (BAX): Wells Fargo Lowers Price Target to $33 | BAX Stock News - GuruFocus
Baxter (BAX) Target Price Reduced by Stifel Amid Strong Q1 Results | BAX Stock News - GuruFocus
Wells Fargo Adjusts Baxter International Price Target to $33 From $36 - marketscreener.com
Citigroup Adjusts Price Target on Baxter International to $34 From $35 - marketscreener.com
JPMorgan Adjusts Price Target on Baxter International to $34 From $36 - marketscreener.com
Here's Why Baxter International (NYSE:BAX) Has A Meaningful Debt Burden - simplywall.st
Press Release Distribution & PR Platform - ACCESS Newswire
Baxter International Inc (BAX) Q1 2025 Earnings Call Highlights: Strong Sales Growth and EPS ... - Yahoo
Baxter International Inc (BAX) Q1 2025 Earnings Call Highlights: Strong Sales Growth and EPS Surpass Expectations - GuruFocus
Baxter International Reports Strong Q1 2025 Results - TipRanks
State of Tennessee Department of Treasury Sells 69,945 Shares of Baxter International Inc. (NYSE:BAX) - MarketBeat
Baxter International Surpasses Q1 2025 Expectations - TipRanks
Baxter International, Deerfield-based maker of IV fluid and pharmaceuticals, expects tariff impact of $60 to $70M - Chicago Tribune
Balanced Outlook on Baxter International: Strong Performance with Margin Concerns - TipRanks
Baxter International Inc. 2025 Q1ResultsEarnings Call Presentation (NYSE:BAX) - Seeking Alpha
Baxter Earnings: Elevated Medical Utilization Mildly Boosts 2025 Outlook Despite Tariff Concerns - Morningstar
Baxter Still in Turnaround Mode Following Weak Postpandemic Results and Renal Divestiture - Morningstar
Evercore ISI Adjusts Baxter International Price Target to $44 From $45, Maintains Outperform Rating - marketscreener.com
Baxter International (BAX) Stock Climbs on Strong Earnings and R - GuruFocus
BAX Stock Gains Following Q1 Earnings Beat Estimates, Revenues Up Y/Y - TradingView
Baxter Reports Strong Medical Devices Sales In Q1, Lifts 2025 Guidance, Stock Jumps - Benzinga
Baxter stock rises on earnings beat, guidance raise (BAX:NYSE) - Seeking Alpha
Baxter International Surpasses Revenue Expectations in Q1 2025News and Statistics - IndexBox
Earnings call transcript: Baxter International beats Q1 2025 expectations - Investing.com
Earnings call transcript: Baxter International beats Q1 2025 expectations By Investing.com - Investing.com India
Baxter’s (NYSE:BAX) Q1: Beats On Revenue - Yahoo Finance
Baxter (BAX) Reports Q1 Earnings: What Key Metrics Have to Say - Yahoo Finance
Baxter posts strong U.S. sales, anticipates $60M hit from tariffs - Crain's Chicago Business
Baxter (BAX) Surpasses Q1 Revenue Forecast Amid Strategic Transf - GuruFocus
Baxter (BAX) Updates Sales and Earnings Outlook | BAX Stock News - GuruFocus
Baxter tops quarterly estimates on strong demand for medical devices - TradingView
Baxter International's Q1 Adjusted Net Income Drops, Revenue Rises; Full-Year 2025 Guidance Revised - marketscreener.com
Baxter Q1 2025 slides: Sales beat expectations, EPS surges 53%, guidance raised - Investing.com Australia
Baxter International Inc Surpasses Q1 2025 Estimates with $0.55 EPS and $2.63 Billion Revenue - GuruFocus
Baxter Reports First-Quarter 2025 Results - Baxter
Baxter Reports First-Quarter 2025 Results | BAX Stock News - GuruFocus
Baxter International Boosts FY25 OutlookUpdate - Nasdaq
Baxter International Inc. Q1 Profit Increases, Beats Estimates - Nasdaq
Baxter shares rise as Q1 earnings top estimates, guidance raised - Investing.com Australia
Finanzdaten der Baxter International Inc-Aktie (BAX)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.84%
0.49%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):